Abingem, with gemcitabine as its main component, is a type of nucleoside analog. It is a chemotherapy medication for cancer like lung cancer, pancreatic cancer, breast cancer, and ovarian cancer. The treatment suppresses the body’s ability to produce new cancer cells.
Gemcitabine (dFdC), which is a pyrimidine antimetabolite, is metabolised intracellularly by nucleoside kinase to the active diphosphate (dFdCDP) and triphosphate (dFdCTP) nucleosides. The cytotoxic action of gemcitabine is due to the inhibition of DNA synthesis by two actions of dFdCDP and dFdCTP. First, dFdCDP inhibits ribonucleotide reductase, which is uniquely responsible for catalyzing the reactions that generate the deoxynucleoside triphosphates (dCTP) for DNA synthesis. Inhibition of this enzyme by dFdCDP causes reduction in the concentrations of deoxynucleosides in general, and especially in that of dCTP. Second, dFdCTP competes with dCTP for incorporation into DNA (self-potentiation).
Use this medication precisely as recommended by your physician. Follow the prescription of your doctor carefully.
Your physician’s medication dose is based on your condition, other medications or food supplements you may take, and your reaction to treatment. To diminish your risks for adverse effects, don’t increase your dosage; take it regularly or as instructed by your physician. Adverse events may still happen even at usual prescription dosages.
If your physician requests you to use this drug consistently, use it regularly to get the most benefits from it. Take it daily at a fixed time to make you remember it better.
Your doctor may need to modify your dosages to ease your symptoms or if you develop adverse reactions.
If you have any inquiries regarding information, ask your physician or pharmacist.
